7 RESULTS
COMMENT Our experience working with α-synuclein is similar to Lashuel and colleagues’ in that we always recover α-synuclein as monomers. We have never observed tetramers using similar biochemical and biophysical techniques in the analyses of recombinant α ...
COMMENT Picking the Right Model of Neurodegeneration for Drug Discovery for Patients With Sporadic Amyotrophic Lateral Sclerosis Comment by John Q. Trojanowski and Virginia M.-Y. Lee Despite significant heterogeneity within frontotemporal lobar degeneration (FTLD ...
COMMENT In this paper, Yuan et al. report elegant studies of axonal transport in vivo using tau transgenic and tau knockout mice that overexpress human tau isoforms or completely lack tau expression, respectively. These studies sought to elucidate the ...
COMMENT These studies are spectacular advances in FTD research that open up new avenues for understanding mechanisms of FTLD-U. Notably, since progranulin proteins, or derivatives thereof, were not found in the ubiquitin inclusions of these FTLD-U disorders, it ...
COMMENT The Mandelkows have managed to decipher the x-ray crystallographic structure of the part of MARK2 that is involved in the regulation of the binding of tau to microtubules through phosphorylation at specific sites. This is clearly a major and important ...
COMMENT This paper demonstrates a much higher incidence of dementia in PD patients than previously reported. This might reflect the disease mechanisms we investigate in our current paper, Giasson et al., 2003. The percentage of patients with Parkinson’s disease ...
COMMENT The Wilson et al. paper is relevant to the findings in our paper. While the authors do not establish the extent of co-morbid tau and α-synuclein in their patient cohort, it is likely that this is occurring, and it emphasizes once again the clinical ...
